% | $
Quotes you view appear here for quick access.

Мабвакс Терапевтика Message Board

  • ironscheme ironscheme Jan 31, 2013 1:22 PM Flag

    TELK may be an aggressive buy

    TELK's Telintra induces cellular death of leukemia cells while simultaneously promoting new bone marrow and blood cell production. The phase II trial data has shown extended Telintra dosing improves blood cell counts cutting dependence on blood cell transfusions.

    Celgene's Revlimid in combination with Telintra is effective and safe in low - risk MDS patients. These findings are published in the Journal of Hematology and Oncology. Celgene's global Revlimid sales total was $2.47 Billion in 2010. The American Cancer Society says over 20,000 new cases of MDS are diagnosed each year.... while GlobalData found there is a high unmet need, implying the market is not served well with current treatment options.

    Potential partnering here? You bet Celgene's interested.

    Using Due diligence of your own I'm sure you will agree and find TELK undervalued next to peers.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.46+0.13(+9.77%)Jul 10 4:00 PMEDT